POST Online Media Lite Edition


Agile Therapeutics adds John Hubbard to its board

Staff writer |
Princeton, N.J., USA - November 19, 2014, Princeton, N.J., USA - Agile Therapeutics, Inc., a women's health specialty pharmaceutical company, announced that John Hubbard has been appointed to the company's board of directors.

Dr. Hubbard will serve on Agile's Nominating and Corporate Governance Committee. Dr. John Hubbard currently serves as Senior Vice President and Worldwide Head of Development Operations for Pfizer Inc., and is responsible for the global clinical trial operations and management of more than 450 clinical projects from Phase 1 to 4.

He recently announced that he will leave Pfizer in January 2015, to pursue an executive leadership role in the healthcare services area.

Dr. Hubbard has been leading pharmaceutical research and development activity for nearly thirty years and held positions of increasing responsibility in the biopharmaceutical and clinical research & development services industries.

Prior to joining Pfizer in 2010, he was Group President, Clinical Research Services at ICON Clinical Research, a global clinical research organization, where he was responsible for the global business and operations.

During his career, Dr. Hubbard has been directly responsible for drug discovery and non-clinical pharmacology, clinical pharmacology, project management, product development optimization, commercial assessment of new chemical entities, and clinical development operations.

He has led several drug development teams to successful commercialization of new chemical entities and has participated at FDA meetings to support end of Phase 2 and end of Phase 3 data presentations for psychiatric, neurological, cardiovascular, and anti-infective drugs.

He is a member of the Society of Clinical Pharmacology and Therapeutics, Drug Information Association and served on the Special Interest Advisory Committee on Project Management.

He also served as Chairman of the Fellow of the American College of Clinical Pharmacology (ACCP) Public Policy Committee from 1999 to 2007. Dr. Hubbard is a Board Certified Diplomat in Applied Pharmacology and elected to Fellow of the ACCP in 1994.

Dr. Hubbard received a Bachelor of Science degree in Biopsychology from the University of Santa Clara and a Doctorate from the University of Tennessee, with a research focus on the genetic basis of hypertension and autonomic dysfunction.

He was a National Institute of Health Postdoctoral Fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center.

Dr. Hubbard has authored and co-authored several book chapters and published numerous articles and abstracts in the areas of biopsychology, cardiovascular and autonomic pharmacology, clinical pharmacology, and global drug development.


What to read next

Bioclinica names John Hubbard CEO
Agile Therapeutic: Al Altomari new president and CEO
Willbros names VP, gas processing, Tulsa operations